Blood volatile organic compounds as potential biomarkers for amyotrophic lateral sclerosis: an animal study in the SOD1 G93A mouse.
Amyotrophic lateral sclerosis (ALS) is a rapid progressive motor neuron disease. Currently, there are no specific or reliable biomarkers for the diagnosis of this disease, and there are no effective medical treatments. The early diagnosis and treatment of this disease has the potential to prolong the survival of ALS patients, but typically, approximately 1 year passes between the onset of symptoms and the diagnosis of this disease. Therefore, there is an urgent need to find specific biomarkers to enable early diagnosis and therapeutic intervention in this disease. Analyzing the volatile organic compounds (VOCs) present in the blood and exhaled breath is a useful and convenient approach for investigating potential biomarkers. In this study, we examined the VOCs present in blood samples from copper zinc superoxide dismutase 1 (SOD1) glycine to alanine mutation at position 93 (G93A) mice to determine whether a specific biomarker pattern exists in these transgenic mice. Blood samples from ALS mice and their age-matched littermates were analyzed using gas chromatography-mass spectrometry. A total of 12 independent compounds associated with oxidative stress were identified at the early stage of disease. The data show that there is a specific pattern of blood VOCs in ALS mice that could potentially be used as biomarkers that could improve the diagnosis of this disease. Furthermore, these compounds could also potentially be used to monitor the response to neuroprotective agents and to help us better understand the underlying mechanisms of ALS.
Department of Neurology, the First Affiliated Hospital of Harbin Medical University, Harbin, 150001, Heilongjiang, China.
Hongquan
H
Jiang
Department of Anesthesiology, the First Affiliated Hospital of Harbin Medical University, Harbin, 150001, Heilongjiang, China.
Changsong
C
Wang
Department of Neurology, the Affiliated Hospital of Weifang Medical University, Weifang, 150001, Shandong, China.
Ming
M
Ren
Department of Neurology, the First Affiliated Hospital of Harbin Medical University, Harbin, 150001, Heilongjiang, China.
Xiang
X
Yin
Department of Anesthesiology, the First Affiliated Hospital of Harbin Medical University, Harbin, 150001, Heilongjiang, China.
Chunjie
C
Chi
Department of Anesthesiology, the First Affiliated Hospital of Harbin Medical University, Harbin, 150001, Heilongjiang, China.
Lei
L
Guo
Department of Biostatistics, School of Public Health, Harbin Medical University, Harbin, 150086, Heilongjiang, China.
Chaofu
C
Ke
Department of Neurology, the First Affiliated Hospital of Harbin Medical University, Harbin, 150001, Heilongjiang, China. fenghonglin321@sina.com.
Honglin
H
Feng
Department of Anesthesiology, the First Affiliated Hospital of Harbin Medical University, Harbin, 150001, Heilongjiang, China. enyouli@aliyun.com.
Enyou
E
Li
D000690:Amyotrophic Lateral Sclerosis / Q000097:blood* / Q000235:genetics; D000818:Animals; D015415:Biomarkers / Q000097:blood; D051379:Mice; D020125:Mutation, Missense; D013482:Superoxide Dismutase / Q000378:metabolism*; D000072105:Superoxide Dismutase-1; D055549:Volatile Organic Compounds / Q000097:blood*
D015415:Biomarkers; D055549:Volatile Organic Compounds; C000606291:Sod1 protein, mouse; D013482:Superoxide Dismutase; D000072105:Superoxide Dismutase-1